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Summary 
An immunological  basis has been postulated for the strong association between at least five subtypes 
of the HLA-B27 allele (B27.01, .02,  .04, .05, and .06) and ankylosing spondylitis, namely that 
cytotoxic T  lymphocyte (CTL) responses  are induced against an "arthritogenic" peptide that 
these different subtypes can all present. This requires  a degree of overlap between the peptide 
binding repertoires of different B27 molecules. The present work, using CTL responses to Epstein- 
Barr virus (EBV) as a model system in which to identify B27-restricted  epitopes, provides the 
first direct evidence that different disease-related alleles can present the same immunodominant 
peptide. We first noted that EBV-specific CTL clones, whether from B27.05-, B27.02-, or B27.04- 
positive donors, were largely subtype-specific  in their restriction, recognizing only EBV-transformed 
B cell lines of the relevant B27 subtype. However, when tested against targets expressing individual 
EBV proteins from recombinant vaccinia virus vectors, all B27.05-restricted,  all B27.02-restricted, 
and a proportion of B27.04-restricted  clones were reactive to the same viral nuclear antigen, 
Epstein-Barr nuclear antigen (EBNA)3C.  In subsequent peptide sensitization assays, all  the 
EBNA3C-specific clones tested and also the EBNA3C-specific component within polyclonal CTL 
preparations from B27.05-,  B27.02-,  or B27.04-positive  donors recognized the same immuno- 
dominant viral peptide RRIYDLIEL (EBNA3C residues 258-266). This sequence accords well 
with the proposed B27.05 peptide motif and clearly must be accommodated within the different 
peptide binding grooves of B27.05, B27.02,  and B27.04 molecules.  Clonal analysis revealed a 
second component of the B27.04-restricted response that was not shared with other subtypes. 
This was  directed against an EBV latent membrane protein LMP2 epitope whose sequence 
RRRWR,  RLTV satisfies some but not all requirements of the B27.05 peptide motif. We conclude 
that there is indeed a degree of functional overlap between different B27 subtypes in their selection 
and presentation of CTL epitopes. 
T 
he role of HLA class I molecules is to bind peptide frag- 
ments of endogenously synthesized cellular or viral pro- 
teins and to present these as HLA-peptide complexes at the 
cell surface for recognition by CTLs (1-4).  Stability of the 
complex requires a high affinity interaction between the pep- 
tide and the peptide binding groove (5). Because the precise 
structure of the groove is affected by HLA polymorphism 
(6), any one particular class I allele will present a particular 
selection of peptides (7). The concept is best illustrated with 
reference to the HLA-B27.05 molecule, for which a detailed 
x-ray crystallographic structure is now available (8, 9) and 
where elution and microsequence analysis of naturally pro- 
cessed peptides has identified certain shared features of a B27.05 
allele-specific peptide motif (10). In this motif, the consis- 
tent presence of an arginine at position 2 can be understood 
in terms of the high affinity of this amino acid's side chain 
for the "B" pocket in the B27.05  peptide binding groove. 
Likewise, other structural constraints appear to favor the pres- 
ence of hydrophobic residues at position 3 and of positively 
charged amino acids at the NH2- and COOH-terminal po- 
sitions 1 and 9 (8-10). 
HLA-B27.05 is the most common of seven distinct sub- 
type alldes (B27.01-B27.07)  which together make up the 
serologically defined HLA-B27 family of class I molecules. 
These subtypes differ from one another in a limited number 
of amino acid residues occupying defined positions in the 
c~-hdical sides or B-pleated sheet floor of the peptide binding 
groove (11, 12). Interest in the B27 family stems from its 
very strong linkage with ankylosing spondylitis and related 
spondyloarthropathies (13, 14). This represents  by far the 
dearest example of an HLA-linked disease in humans, and, 
indeed, there are strong grounds for believing that HLA- 
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probably as targets of an immunopathological  response. Of 
several mechanisms proposed in this regard (16),  one of the 
most interesting postulates a role for CTL responses directed 
against  an "arthritogenic"  peptide,  of cellular or microbial 
origin, which is selectively presented by HLA-B27 (17).  In 
this context, at least five of the above B27 subtypes are known 
to be disease linked. These are the widespread B27.05 sub- 
type, the B27.01 and B27.02 subtypes found in Caucasian 
populations,  and the B27.04 and B27.06 subtypes found in 
South East Asian populations (16,  18).  The implication is, 
therefore, that all five B27 subtype molecules must be capable 
of binding and presenting the same arthritogenic peptide de- 
spite differences in  the  structure  of their  peptide binding 
grooves. 
Leaving aside the specific question of the identity of such 
an arthritogenic  peptide, here we address the more general 
question that this interpretation raises, namely, is there demon- 
strable overlap between the range of peptide antigens presented 
as CTL epitopes by different B27 molecules? The model system 
we have used for this purpose involves CTL responses to EBV, 
a herpesvirus widespread in human populations and carried 
by all previously infected individuals as a latent infection of 
B lymphoid tissues (19).  All healthy virus carriers  possess 
memory CTLs to EBV, and these can be reactivated by ap- 
propriate  in  vitro  stimulation  with  the  autologous  EBV- 
transformed  B  lymphoblastoid  cell line  (LCL) 1 (20).  The 
present  work identifies the dominant  viral target  epitopes 
presented by three different B27 subtypes, B27.05, B27.02, 
and B27.04,  each of which is disease linked.  Remarkably, 
despite the number of viral proteins available for recognition 
in this herpesvirus system, all three B27 subtypes present the 
same immunodominant  viral peptide. 
Materials and Methods 
B27-positive Donors.  Six B27-positive individuals, all previously 
infected by EBV, were used in this work: SC (HLA-A2, A2, B27.05, 
B27.05), RT (HLA-A2, A24, B27.05, B35), EN (HLA-A1, A2, 
B18, B27.05), LY (HLA-A1, A24, B27.02, B35), DH (HLA-A2, 
All,  B27.04, B40), and DW (HLA-A2, A24, B13, B27.04). 
Target Cells.  EBV (B95.8 strain)-transformed  LCLs were es- 
tablished from each of the above donors by in vitro infection of 
PBMC; other LCLs from donors of known B27 subtype were kindly 
provided by Professor A. J. McMichael (University of Oxford, Ox- 
ford, UK), Dr. L. MacLean (Northwick Park Hospital,  London, 
UK), Dr. B. S. Breur-Vriesendorp (Central Laboratory of Nether- 
lands Red Cross, Amsterdam, The Netherlands), and Dr. A. Lopez 
de Castro  (University of Madrid,  Madrid,  Spain). EBu 
target ceils included PHA-stimulated  T lymphoblasts maintained 
in IL-2-conditioned medium and used in CTL assays from 14 d after 
stimulation, and fibroblasts established from skin biopsies and main- 
tained in standard monolayer culture. 
Generation ofEBVspecific CTL.  PBMC from the above donors 
were cocultivated with "/-irradiated cells of the autologous  EBV 
(B95.8)-transformed LCL (responder to stimulator ratio of 40:1), 
and the resultant EBV-specific  polyclonal CTL preparations main- 
tained in IL-2-conditioned medium as described (21). EBV-specific 
1 Abbreviations used in this paper: EBNA, Epstein-Barr nuclear antigen; 
LCL, lymphoblastoid cell line; LMP, latent membrane protein. 
CTL clones were generated from cocultures at day 4 after stimula- 
tion by seeding in semi-solid agarose as described (22). After estab- 
lishment, clones were maintained by weekly refeeding in medium 
containing 20 U/ml rlL2 (kindly provided by Glaxo Ltd., London, 
UK) and 20%  vol/vol supernatant  of the IL-2-producing  MLA- 
144 cell line, and by weekly stimulation with ~/-irradiated autolo- 
gous LCL cells. 
Vaccinia Virus Recombinants.  The generation  of vaccinia virus 
recombinants encoding the EBV latent proteins (Epstein-Barr nu- 
clear antigens [EBNAs] 1, 2, 3A, 3B, 3C, LP, and latent  mem- 
brane proteins [LMP]I and 2) has been described previously (23, 
24). All coding sequences for EBV latent proteins were of B95.8 
strain origin  (25). 
Synthetic Peptides.  Peptides  were synthesized using fluorenyl- 
methoxycarbonyl chemistry by Dr. J. Fox (Alta Bioscience, Univer- 
sity of Birmingham).  Peptides were dissolved in DMSO and as- 
sayed for protein concentration by a modification of the Biuret assay 
(26) before storage at  -20~ 
Cytotoxicity  Assays.  Effector  CTLs  from  each donor  were 
screened in a standard 4-h 51Cr-release assay. E/T ratios were be- 
tween 2:1 and 8:1 for CTL clones and between 5:1 and 15:1 for 
polyclonal  CTL preparations.  The  use of recombinant  vaccinia 
virus-infected  fibroblasts in cytotoxicity assays has been described 
previously (24). Briefly, monolayer cultures of fibroblasts were ex- 
posed to recombinant vaccinia virus (multiplicity of infection 10) 
for 2 h, then additional culture medium added for 16 h. Infected 
cultures were then harvested by trypsinization, labeled for 1 h with 
SlCrO4, washed three times, and used as targets in the standard 
CTL assay. 
In peptide sensitization assays, PHA blasts were labeled with 
S1CrO, for 2 h, washed twice,  then incubated with peptide at a 
concentration  of either 40/~g/ml for 15-mer peptides or 4/xg/ml 
for 10/9-mer peptides in a volume of 100 pl. After 1 h, CTLs were 
added in a 100-/~1 volume to give final peptide concentrations  of 
20 and 2/~g/ml,  respectively for the duration  of the assay. 
Results 
B27 Subtype Restriction of EBV-specific  CTL Responses.  An 
initial series of experiments asked to what extent EBV-specific 
CTLs reactivated in vitro from donors of known B27 sub- 
type were capable of recognizing EBV-positive LCL targets 
of other subtypes. Since the B27-positive donors to be studied 
shared certain other HLA class I alleles, it was necessary to 
analyze their  B27-restricted  effectors as clones rather  than 
within polyclonal CTL populations. Clones showing opera- 
tional specificity for EBV (i.e.,  recognizing  the autologous 
LCL but not autologous PHA blasts) and B27 restriction (i.e., 
recognizing a B27 subtype-matched LCL) in initial screening 
assays were expanded and tested against a panel of LCL targets 
expressing one of six different B27 subtypes, B27.01-B27.06. 
Fig. 1 shows data from representative dones derived from 
a 827.05-positive donor SC, a B27.02-positive donor LY, and 
a B27.04-positive donor DH.  All the B27.05-positive SC 
clones (SCc2 and SCc39 are representative of 10 clones tested) 
were entirely subtype-specific in their restriction,  showing 
char recognition of B27.05 LCL targets but not of any other 
LCLs in the B27 pand.  Similar results were obtained with 
five CTL clones analyzed from a second B27.05-positive donor 
RT (data not shown). Of the B27.02-positive LY dones tested 
7/33 (e.g., LYe21) were also subtype specific, recognizing only 
B27.02 LCL targets.  However, another  26 LY clones (e.g., 
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Figure  1.  B27 subtype restriction of EBV-speci- 
fic CTL responses. Representative B27-restricted 
CTL clones from B27.05-positive donor SC (A2, 
B27.05),  B27.02-positive  donor  LY  (A1,  A24; 
B27.02, B35), and B27.04-positive donor DH (A2, 
All; B27.04,  B40) were tested against a panel of 
I_CL targets (including the autologous I.CL) re- 
presenting the six B27 subtypes B27.01-B27.06. 
E/T ratios were between 2:1 and 8:1. Results are 
expressed as percent specific lysis and are illustra- 
tive of those in several repeated  assays. 
LYc38) were capable of recognizing not only B27.02, but also 
B27.05 LCLs. All B27.04-positive DH clones assayed on the 
same panel (DHcl and DHc50 are representative of 23 clones 
tested) were specific for B27.04 LCL targets only. 
EBV Target Antigen  Specificity of B27-restricted CTL Re- 
sponses.  Viral antigen expression in EBV-transformed LCLs 
is thought to be limited to eight latent proteins. These are 
EBNAs 1, 2, 3A, 3B, 3C, and -LP, and LMPs 1 and 2 (27). 
In a recent study, we mapped the viral antigens being recog- 
nized by polyclonal EBV-specific CTL populations by using 
recombinant vaccinia virus vectors to express these latent pro- 
teins individually in appropriate target cells (24). Adopting 
the same approach here, as many as possible of the above B27- 
restricted CTL clones were then assayed on autologous fibro- 
blast targets infected with the recombinant vaccinias. 
The results are illustrated in Fig. 2, again using data from 
the same representative clones. All 8 B27.05-posifive SC clones 
tested in this way (e.g., SCc2, SCc39) recognized targets ex- 
pressing the EBNA3C viral protein, whereas lysis of all other 
vaccinia-infected  targets remained at background levels. A 
similar result was obtained with four clones from a second 
B27.05-positive donor RT (data not shown). Furthermore 
all 15 B27.02-positive LY clones tested, whether they dis- 
played subtype-specific restriction (e.g.,  LYc21) or B27.02/ 
B27.05 restriction (e.g., LYc38), also mapped to the EBNA3C 
target antigen. Assays on 35 B27.04-positive DH clones pro- 
duced two patterns of results. Four clones (e.g., DHcl) again 
mapped to EBNA3C, whereas another 31 clones (e.g., DHcS0) 
recognized a different viral protein, LMP2. 
Identification of B27-restricted Peptide Epitopes in EBNA3C. 
Since EBNA3C appeared to be a common target protein for 
CTL responses restricted through three different B27 sub- 
types, we sought to determine the epitope specificity of these 
responses using synthetic peptides. In an initial series of ex- 
periments, we screened a panel of 15-mer peptides (each over- 
lapping by 10 amino acids and spanning the entire 938 amino 
acid sequence of EBNA3C) for their ability to sensitize au- 
tologous PHA blast targets to CTL recognition. Because of 
the requirement for large numbers of effectors, these assays 
used polyclonal CTL preparations from B27 subtyped donors 
that were known to contain a dominant B27-restricted com- 
ponent and to recognize EBNA3C by recombinant vaccinia 
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Figure  2.  Analysis of EBV target antigens recognized by 
the same representative B27-restricted CTL clones from donors 
SC, LY, and DH as used in Fig. 1. Individual clones were 
tested against autologous fibroblasts either uninfected (uninJ) 
or preinfected with recombinant vaccinia viruses (Vacc-) ex- 
pressing the individual EBV latent proteins EBNAs 1, 2, 3A, 
3B, 3C, -LP, and LMPs  1 and 2. E/T ratios were between 
2:1 and 8:1. Results are expressed as percent specific lysis and 
are illustrative of those seen in several repeated  assays. virus mapping (24). We found that CTL preparations of this 
kind from the B27.05-positive donor RT, the B27.02-positive 
donor  LY,  and  the  B27.04-positive  donor  DH  all  gave 
significant  killing against  one particular  15-mer  peptide, 
EBNA3C residues  256-270  (data not shown). 
The result was confirmed and extended in subsequent ex- 
periments where the CTL preparations were screened against 
an independent panel of 10-met peptides representing all pos- 
sible EBNA3C sequences with an arginine residue at posi- 
tion 2, i.e., all peptides satisfying  the primary requirement 
of the B27.05 peptide motif (10). Fig.  3 shows the overall 
results expressed as mean target cell lysis +  SD from six to 
eight such assays per donor, in each case involving effector 
CTLs from at least three independent activations  from pe- 
ripheral blood. Significant  levels of lysis above the general 
background were observed for two overlapping 10-met pep- 
tides (EBNA3C residues 257-266 and 258-267) with all three 
effector populations, i.e., with B27.05-positive  RT CTLs, 
with B27.02-positive LY CTLs and with B27.04-positive DH 
CTLs.  Polyclonal  CTLs  from two  other  B27.05-positive 
donors, SC and EN, also showed reactivity only against the 
above two peptides (data not shown). Significantly, these over- 
lapping sequences both lay within the particular  15-mer pep- 
tide (EBNA3C  residues  256-270)  identified in the initial 
screening experiments. None of the other 10-met peptides 
gave reproducible lysis above background with any of the 
CTL  preparations  tested,  with  the  single  exception  of 
EBNA3C residues 249-258.  This sequence was recognized 
by some but not all polyclonal CTL preparations from the 
B27.05  donor RT, though not by any other donor. 
Having  used polydonal  CTLs  in  these initial  peptide 
screening assays, we then tested the CTL clones for their ability 
to recognize the two 10-mer peptides 257-266 and 258-267 
and the shared 9-met 258-266 (sequence RRIYDLIEL). Of 
the  B27-restricted  clones  that  had  been  mapped  to  the 
EBNA3C target protein in recombinant vaccinia experiments, 
all of those that were still available for testing in peptide sen- 
sitization experiments proved to be specific for the 258-266 
epitope. Fig.  4 shows the results obtained when the same 
representative panel of B27.05, B27.02, and B27.04-positive 
CTL clones used in Figs. 1 and 2 were assayed on PHA blasts 
of the three different B27 subtypes preexposed to EBNA3C 
peptides 257-266,  258-267,  and 258-266.  All five B27.05- 
positive SC clones tested in this way (e.g., SCc2) recognized 
the 258-266 epitope on B27.05-positive blasts but not on the 
other two subtypes.  Furthermore, three CTL clones from 
the second B27.05-positive  donor RT gave the same result 
(data  not shown). Interestingly, all 13 B27.02-positive  LY 
clones tested, whether entirely B27.02 restricted (e.g., LYc21) 
or B27.02/B27.05 restricted (e.g., LYc38) in the earlier anal- 
ysis (see Fig. 1), were able to recognize the 258-266 epitope 
when presented on B27.02 and B27.05  blast cells. Finally, 
two B27.04-positive DH clones showing EBNA3C specificity 
(e.g., DHcl) likewise recognized the 258-266 epitope but only 
when presented on a B27.04 background. Included as con- 
trols in the above experiment were three other EBNA3C pep- 
tides (79-88, 254-263, and 255-264) whose sequences matched 
the B27.05 peptide motif as closely as the 258-266 epitope 
itself. These peptides never mediated significant lysis by B27- 
restricted effectors. 
We also had access to a limited number of cryopreserved 
lymphocytes from a second B27.04-positive donor, DW, who 
in earlier studies had been found to generate a B27.04-restricted 
EBV-specific CTL response (28). Cloning experiments from 
this lymphocyte sample yielded a single B27.04-restricted CTL 
clone and this also mapped to the same EBNA3C 258-266 
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Figure 3.  Peptide epitopes recognized by 
EBNA3C-specific, B27-restricted polyclonal 
CTLs. Selected 10-mer peptides from the 
EBNA3C sequence were screened for their 
ability to sensitize PHA blast targets to au- 
tologous EBV-specific  polyclonal CTL prep- 
arations from the B27.05-positive donor RT 
(A2, A24; B2Z05, B35), from the B27.02- 
positive donor LY (A1, A24; B2Z02, B35), 
and from the B27.04-positive  donor DH 
(A2, All; B2Z04, B40). Results are a com- 
pilation of data from three independent 
polyclonal CTL activations from each donor 
and  are  expressed  as  the  mean  percent 
specific lysis (_+SD) observed in a total of 
six to eight replicate assays per donor. E/T 
ratios were between 5:1 and 15:1. For all 
three CTL donors, average levels of back- 
ground tysis up to 10% were observed for 
control PHA blast targets not exposed to 
peptides. Peptides are identified by numbers 
indicating their position in the EBNA3C 
primary sequence (42). The panel includes 
all possible EBNA3C peptides with an ar- 
ginine residue at position 2. 
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Figure 4.  Peptide  epitopes  recognized  by  EBNA3C-specific, 
B27-restricted CTL clones. Representative B27-restricted, 
EBNA3C-specific  CTL clones  from  donors SC, LY, and DH 
(as in Fig. 1) were tested against the 10-mer peptides 257- 
266,258-267, and their  shared  9-mer 258-266. Other 10-met 
peptides 79-88, 254-263, and 255-264 were  included  as nega- 
tive controls. These  peptides  (along  with the 258-266 sequence) 
show the best correlations within EBNA3C with the pro- 
posed B27.05 peptide  motif  (10). All CTL clones  were tested 
on PHA blast targets representing the three B27 subtypes, 
B27.05, B27.02, and B27.04. E/T ratios were between 2:1 
and 8:1. Results  are expressed as percent specific  lysis  and are 
illustrative of those seen in several repeated assays. 
peptide when screened on PHA blast targets from the B27.04- 
matched donor DH (data not shown). A summary of results 
from the analysis of EBNA3C-specific  CTL responses in B27- 
positive donors is presented in Table  1. 
Identification of B27.04-restricted Epitope in LMP2.  A final 
series of experiments sought to determine the peptide epi- 
tope specificity of the B27.04-restricted  DH CTL clones that 
had recognized LMP2 rather than EBNA3C in the original 
recombinant vaccinia experiments (see Fig.  2).  In this case, 
we screened all available clones against a panel of 16 selected 
peptides from the LMP2 sequence, namely all possible 9-mers 
with an arginine residue at position 2. All 17 DH clones tested 
in this way showed clear  reactivity against a single 9-mer 
representing LMP2 residues 236-244 (sequence RRRWKR- 
LTV); none of the other LMP2 peptides were recognized. 
Data from two representative clones (DHc37, DHc50) are 
shown in Fig. 5 from assays in which the LMP2 9-met pep- 
tides were presented on autologous B27.04-positive PHA blasts 
and also on B27.05 and B27.02-positive PHA blasts.  The 
B27.04 restriction apparent in earlier  experiments on LCL 
targets was again in evidence, reactivity against the cognate 
peptide 236-244 only being observed on B27.04-positive target 
cells. This LMP2 epitope is included in the overall summary 
of B27-restricted CTL responses  shown in Table  1. 
Discussion 
The existence of allelic polymorphism within the serolog- 
ically defined HLA-B27 family was first highlighted by work 
on alloreactive and virus-specific CTL responses (29-32), and 
many of the different subtype molecules thus identified proved 
to be distinguishable in isoelectric focusing studies (33, 34). 
The ability ofT cells to discriminate between targets expressing 
different B27 subtypes is best documented for allo-CTL clones, 
Table  1.  Summary of EBV-coded CTL Epitopes Presented by B27 Subtypes 
B27  Effector  Epitope  Epitope 
Donor  Subtype  CTLs  location  sequence 
SC  27.05  Polyclonal +  clones  EBNA3C 258-266  RRIYDLIEL 
EN  27.05  Polyclonal  EBNA3C 258-266  KKIYDLIEL 
RT  27.05  Polyclonal +  clones  EBNA3C 258-266  RRIYDLIEL 
Polyclonal  EBNA3C 249-258  LRGKWQRRYR* 
LY  27.02  Polyclonal +  clones  EBNA3C 258-266  RRIYDLIEL 
DW  27.04  CTL clone  EBNA3C 258-266  RRIYDLIEL 
DH  27.04  Polyclonal +  clones  EBNA3C 258-266  KKIYDLIEL 
CTL clones  LMP2 236-244  RRRWRRLTV 
* Minimal epitope not yet defined. 
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Figure 5.  Peptide epitopes recognized by LMP2-specific, 
B27.04-restricted CTL clones. Representative B27.04-restric- 
ted, LMP2-specific CTL clones from donor DH (A2, All, 
B27.04, B40) were tested on all possible 9-mer peptides from 
the LMP2 sequence containing an arginine residue at posi- 
tion 2. Peptides are again identified by their position in the 
LMP2 primary sequence (43). Clones were tested on PHA 
blast targets  representing  the three B27 subtypes, B27.05, 
B27.02, and B27.04. E/T ratios were between 4:1 and 8:1. 
Results are expressed as percent specific  lysis and are illustra- 
tive of those seen in several repeated assays. 
and by these criteria, none of the natural B27 mutations is 
immunologically silent (32; for a review see reference 11). 
Work to date on B27 molecules as restriction elements for 
antiviral CTL responses leads to a similar conclusion (29-31), 
although some crossrecognition between B27.05 and B27.02 
(35) and between B27.05 and B27.03 (36) has been reported 
using polyclonal  influenza-specific  CTL populations. Through- 
out the above studies, however, there was always a very clear 
distinction between the B27.01/B27.02/B27.05  group and 
the B27.04/B27.06  group of alleles, apparently reflecting a 
key role for the identity of a polymorphic residue at position 
152 in the a2 helix of the peptide binding groove (32). In 
the present work, we have used as probes EBV-specific  CTL 
clones from B27.05-, B27.02-, and B27.04-positive donors. 
As shown in Fig. 1, the majority of such cells were subtype 
specific in their restriction,  the only exception being a subset 
of B27.02-positive clones that could recognize EBV in the 
context of B27.05 as well as B27.02. The effectors in this 
viral system are therefore at least as sensitive to B27 subtype 
polymorphism as allospecific  or influenza-specific  CTLs. This 
established, we went on to examine the EBV antigen specifidty 
of these subtype-restricted  responses. 
Some of the CTL donors used here (SC and RT, B27.05; 
LY, B27.02; DH, B27.04) had been subjects in an earlier survey 
(24) where the dominant B27-restricted component within 
polyclonal CTL populations had mapped to the viral nuclear 
antigen EBNA3C. In the present work, all of the B27.05- 
positive, all of the B27.02-positive, and a subset of the B27.04- 
positive CTL clones established from these same donors like- 
wise mapped to EBNA3C (Fig. 2). Detailed analysis of the 
above responses at the peptide  level gave striking evidence 
of epitope sharing between the different B27 subtypes. Thus 
polyclonal and/or clonal CTLs from three B27.05-positive 
donors, KT, SC, and EN, from one B27.02 positive donor 
LY, and from two B27.04-positive donors DH and DW, all 
recognized the same peptide EBNA3C residues 258-266. This 
clearly  must  be  the  immunodominant  epitope  within 
EBNA3C since it was identified not only from a selected  panel 
of 10-mer  peptides  representing  all  those  sequences that 
satisfied the primary requirement for B27.05 binding, namely 
an arginine at position 2, but also from a complete panel of 
EBNA3C 15-mer synthesized without any bias towards the 
B27.05 peptide motif. Note that these screening assays were 
conducted at relatively high peptide concentrations,  in the 
10-5-10 -6 M range, in order to identify all possible CTL 
epitopes of whatever affinity (37). However, more recent ex- 
periments (data not shown) indicate that the 258-266 pep- 
tide can effectively sensitize B27 targets to CTL lysis at con- 
centrations down to at least 10-9 M, again emphasizing the 
efficiency with which this epitope is recognized. 
The epitope sequence RKIYDLIEL conforms well to the 
proposed B27.05 peptide motif  in having an arginine at posi- 
tion 2,  a positively charged amino acid at position  1,  and 
a hydrophobic residue at position 3. The presence of a hydro- 
phobic residue at position 9, rather than the preferred posi- 
tively charged amino acid, has been noted in certain other 
B27.05-associated peptides (10). The ability of this peptide 
to bind and be presented as an immunodominant CTL epi- 
tope not only by B27.05,  but also by B27.02 and B27.04 
is very significant in view of the known differences between 
these subtypes in the structure of their peptide binding grooves 
(11). On the one hand, conservation of the unique B pocket 
throughout the B27 family of alleles strongly suggests that 
the absolute requirement for arginine at position 2 will be 
maintained in all B27-binding peptides (38). On the other 
hand, relative to B27.05, there are amino acid changes in 
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of the groove) and in B27.04 (affecting positions 77 in the 
or1 helix and 152 in the c~2 helix) which would be antici- 
pated to alter peptide/HLA contacts involving residues  in 
the COOH-terminal region of the peptide. From the CTL 
data, however, it is clear that these subtype changes do not 
preclude binding of the RRIYDLIEL sequence. In fact, mo- 
lecular modeling of the B27.05, B27.02, and B27.04 peptide 
binding grooves suggests that this EBNA3C peptide is ligated 
in an almost identical manner in all three situations (Thorpe, 
C. J.,  D.  S.  Moss,  J.  M.  Brooks,  A.  B.  Rickinson, and 
P.J. Travers, manuscript in preparation), with the effects of 
B27 subtype polymorphism being largely negated by move- 
ment within the bed of water molecules known to be present 
within the B27.05  crystal  structure (9). 
The overall structures of these B27-EBNA3C peptide com- 
plexes must nevertheless be subtly different since they can 
be distinguished by TCR molecules. Thus both B27.05- 
positive CTL clones and B27.04-positive CTL clones only 
recognize target cells expressing their own B27 subtype. This 
is true whether the peptide epitope is generated in target cells 
from  an  endogenously expressed  EBNA3C  protein or  is 
provided exogenously as synthetic peptide (Figs.  1 and 4). 
Interestingly, on LCL targets,  some B27.02-positive CTL 
clones  were capable  of recognizing the  B27.05  subtype, 
whereas other clones were entirely B27.02 restricted (Fig. 
1). However, when optimal concentrations of peptide were 
supplied exogenously, both sets of clones were able to recog- 
nize B27.02  and B27.05 targets (Fig. 4).  In a similar way, 
overexpression of EBNA3C from a recombinant vaccinia virus 
in B27.05-positive  fibroblasts  also allowed crossrecognition 
by CTL clones such as LYc21 which display B27.02 restric- 
tion on LCL targets (data not shown). We presume that such 
crossrecognition involves a low affinity interaction that re- 
quires  higher  numbers  of B27-peptide  complexes to  be 
presented on the cell surface before target cell lysis can be 
achieved. 
The identification of an additional B27.04-restricted CTL 
epitope, which is apparently not recognized by B27.05-  or 
B27.02-positive donors, is very interesting. Thus, whereas 
the dominant EBV-specific reactivity within polyclonal CTL 
preparations from the B27.04-positive donor DH was against 
the EBNA3C epitope (24; Fig. 3, and data not shown), sev- 
eral independent clonings from this donor yielded a majority 
of CTL clones mapping to an epitope within LMP2. The 
sequence of this LMP2 epitope, RRRWRRLTV, is on the 
one hand compatible with the proposed B27.05 peptide motif 
at conserved positions 1, 2, and 9, but incompatible at posi- 
tion 3 where arginine replaces the expected hydrophobic res- 
idue. Molecular modeling indicates that this LMP2 peptide 
can indeed be stably accommodated within the peptide binding 
groove of B27.04, but not of B27.02 or B27.05. This reflects 
the importance of the valine to glutamate substitution at po- 
sition  152  in  the B27.04 groove,  which allows  hydrogen 
bonding between the glutamate side chain and guanidinium 
groups in the side chains of arginine residues at positions 3 
and 5 in the LMP2 peptide (Thorpe, C. J., et al., manuscript 
in preparation). The presence of a valine residue at position 
152 in B27.02 and B27.05 molecules precludes this type of 
interaction. We would suggest therefore that all three sub- 
types can bind peptides strictly adhering to the proposed 
B27.05 motif, but that B27.04 can in addition bind variants 
that contain arginine at positions 3 and 5. 
The present results are particularly significant  in relation 
to the very strong linkage that exists between the HLA-B27 
family of alleles and ankylosing spondylitis. Thus, it has been 
argued  that  CTL  responses  to  an  arthritogenic  peptide 
presented only by B27 molecules might underlie disease patho- 
genesis. This implies that all the B27 subtypes known to be 
disease linked (1327.01, .02, .04, .05, and .06) must be capable 
of presenting the same peptide. Before the present study, the 
only evidence for such epitope sharing between B27 subtypes 
was indirect and came from crossrecognition by rare allospecific 
CTL clones where the identity of the presumed peptide epi- 
tope was not known (39). Here we show in a model system, 
studying CTL responses to a known human pathogen EBV, 
that at least three of the above B27 subtypes (B27.02,  .04, 
and .05) do indeed present the same immunodominant viral 
peptide. Such convergence is remarkable given the extensive 
coding potential of this virus and the range of proteins against 
which, on other HLA backgrounds, EBV-induced CTL re- 
sponses can be directed (24,  40).  In light of these results, 
it will be interesting to extend the present approach to in- 
clude CTL donors of other B27 subtypes.  One might, for 
instance, anticipate similarities between B27.01 and the closely 
related  B27.02 allele, and between B27.06 and the closely 
related B27.04 allele (11). It will be particularly important 
to analyze CTL epitope choice by the B27.03 subtype which, 
though closely related  to B27.05, may not show the same 
disease linkage (41). 
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